Gastric pentadecapeptide BPC 157 in cytoprotection to resolve major vessel occlusion disturbances,ischemia-reperfusion injury following Pringle maneuver,and Budd-Chiari syndrome  

作　　者：Predrag Sikiric Anita Skrtic Slaven Gojkovic Ivan Krezic Helena Zizek Eva Lovric Suncana Sikiric Mario Knezevic Sanja Strbe Marija Milavic Antonio Kokot Alenka Boban Blagaic Sven Seiwerth 

机构地区：[1]Department of Pharmacology,School of Medicine,University of Zagreb,Zagreb 10000,Croatia [2]Department of Pathology,School of Medicine,University of Zagreb,Zagreb 10000,Croatia [3]Department of Anatomy and Neuroscience,Faculty of Medicine Osijek,J.J.Strossmayer University of Osijek,Osijek 31000,Croatia

出　　处：《World Journal of Gastroenterology》2022年第1期23-46,共24页世界胃肠病学杂志（英文版）

基　　金：University of Zagreb,Zagreb,Croatia,No.BM 099.

摘　　要：The stable gastric pentadecapeptide BPC 157 counteracts various venous occlusion-induced syndromes.Summarized are all these arguments,in the Robert’s cytoprotection concept terms,to substantiate the resolution of different major vessel occlusion disturbances,in particular ischemia-reperfusion injury following the Pringle maneuver and Budd-Chiari syndrome,which was obtained by BPC 157 therapy.Conceptually,there is new point(bypassed occluded or ruptured vessel,the equation endothelium maintenance→epithelium maintenance=blood vessel recruitment and activation towards defect or bypassing vessel occlusion),the recruitment of collateral blood vessels to compensate for vessel occlusion and reestablish blood flow.In this paper,we summarize the evidence of the native cytoprotective gastric pentadecapeptide BPC 157,which is stable in the human gastric juice,is a membrane stabilizer and counteracts gut-leaky syndrome.As a particular target,it is distinctive from the standard peptide growth factors,with particular molecular pathways involved,controlling VEGF and NO pathways.In the early 1990s,BPC 157 appeared as a late outbreak of the Robert’s and Szabo’s cytoprotection-organoprotection concept,epithelium,endothelium protection as previous theoretical/practical breakthrough in the 1980s,and brain-gut axis and gut-brain axis.As the time went on,with its reported effects,it is likely most useful theory practical implementation and justification.Meantime,several reviews suggest that BPC 157,which does not have a lethal dose(LD1),has profound cytoprotective activity,used to be demonstrated in ulcerative colitis and invented to multiple sclerosis trials.Likely,it may bring the theory to practical application,starting with the initial argument,no degradation in human gastric juice for more than 24 h,and thereby,the therapeutic effectiveness(including therapeutic per-oral regimen)and pleiotropic beneficial effects.

关 键 词：Gastric pentadecapeptide BPC 157 CYTOPROTECTION Major vessel occlusion disturbances Pringle maneuver Budd-Chiari syndrome Therapy 

分 类 号：R363[医药卫生—病理学]